PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1

PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1

Brief description of study

This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    myeloma
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 29 Jan 2020. Study ID: 826672

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center